- Home
- NVG vs CNTA Comparison
NVG vs CNTA Comparison
Compare NVG & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVG
- CNTA
- Stock Information
- Founded
- NVG 1999
- CNTA 2020
- Country
- NVG United States
- CNTA United Kingdom
- Employees
- NVG N/A
- CNTA N/A
- Industry
- NVG Investment Managers
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- NVG Finance
- CNTA Health Care
- Exchange
- NVG Nasdaq
- CNTA Nasdaq
- Market Cap
- NVG 2.6B
- CNTA 2.3B
- IPO Year
- NVG N/A
- CNTA 2021
- Fundamental
- Price
- NVG $12.38
- CNTA $15.16
- Analyst Decision
- NVG
- CNTA Strong Buy
- Analyst Count
- NVG 0
- CNTA 8
- Target Price
- NVG N/A
- CNTA $23.71
- AVG Volume (30 Days)
- NVG 568.8K
- CNTA 489.7K
- Earning Date
- NVG 01-01-0001
- CNTA 11-12-2024
- Dividend Yield
- NVG 4.65%
- CNTA N/A
- EPS Growth
- NVG N/A
- CNTA N/A
- EPS
- NVG N/A
- CNTA N/A
- Revenue
- NVG N/A
- CNTA $6,853,000.00
- Revenue This Year
- NVG N/A
- CNTA N/A
- Revenue Next Year
- NVG N/A
- CNTA N/A
- P/E Ratio
- NVG N/A
- CNTA N/A
- Revenue Growth
- NVG N/A
- CNTA N/A
- 52 Week Low
- NVG $9.68
- CNTA $7.38
- 52 Week High
- NVG $12.21
- CNTA $18.97
- Technical
- Relative Strength Index (RSI)
- NVG 46.86
- CNTA 41.38
- Support Level
- NVG $12.16
- CNTA $14.44
- Resistance Level
- NVG $12.44
- CNTA $17.65
- Average True Range (ATR)
- NVG 0.13
- CNTA 1.01
- MACD
- NVG 0.03
- CNTA -0.21
- Stochastic Oscillator
- NVG 71.74
- CNTA 20.22
About NVG Nuveen AMT-Free Municipal Credit Income Fund
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.